Non-Small Cell Lung Cancer (NSCLC) - US Drug Forecast and Market Analysis to 2025

  • ID: 4032607
  • Report
  • Region: United States
  • 479 pages
  • GlobalData
1 of 3
Non-Small Cell Lung Cancer (NSCLC) - US Drug Forecast and Market Analysis to 2025

Summary

Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted the treatment landscape towards personalized medicine.

As a drug class, immunotherapeutics are projected to contribute the most to the US market expansion. As a result, both these drug classes are expected to take patient share away from branded chemotherapy, a class that will contract as a whole at a negative CAGR of 18.4%. The growth of the IO drug class will be fueled by the increasing use of immunotherapies across histologies and lines of therapy in NSCLC. The use of PD-1 checkpoint inhibitors in first-line therapy of NSCLC is expected to take away significant sales from conventional chemotherapies that are typically used in the first line.

Scope

- Overview of NSCLC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2015-2025.
- Analysis of the impact of key events as well the drivers and restraints affecting the US NSCLC market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for NSCLC.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2015-2025 in the US.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

3.3 Symptoms

3.4 Prognosis

3.5 Quality of Life

4 Disease Management

4.1 Diagnosis and Treatment Overview

4.1.1 Diagnosis

4.1.2 Treatment Guidelines and Leading Prescribed Drugs

4.1.3 Clinical Practice

4.2 US

5 Competitive Assessment

5.1 Overview

5.2 Product Profiles - Major Brands, Epidermal Growth Factor Receptor-Targeting

5.2.1 Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

5.2.2 Tarceva (erlotinib hydrochloride)

5.2.3 Iressa (gefitinib)

5.2.4 Gilotrif (afatinib)

5.2.5 Tagrisso (osimertinib)

5.2.6 Portrazza (necitumumab)

5.2.7 Conmana (icotinib)

5.3 Product Profiles - Major Brands, Anaplastic Lymphoma Kinase-Targeting

5.3.1 Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors

5.3.2 Xalkori (crizotinib)

5.3.3 Zykadia (ceritinib)

5.3.4 Alecensa (alectinib)

5.4 Product Profiles - Major Brands, Monoclonal Antibodies

5.4.1 Programmed Cell Death Protein 1/Programmed Death Ligand 1 Immune Checkpoint Inhibitors

5.4.2 Opdivo (nivolumab)

5.4.3 Keytruda (pembrolizumab)

5.4.4 Tecentriq (atezolizumab)

5.5 Product Profiles - Major Brands, Other

5.5.1 Avastin (bevacizumab)

5.5.2 Cyramza (ramucirumab)

5.5.3 Vargatef/Ofev (nintedanib)

5.6 Chemotherapies

6 Unmet Needs Assessment and Opportunity Analysis

6.1 Overview

6.2 First-Line Treatments That Extend Overall Survival in Advanced-Stage Nonsquamous NSCLC Without Actionable Mutations

6.2.1 Unmet Need

6.2.2 Gap Analysis

6.2.3 Opportunity

6.3 Therapies Targeting Novel Biomarkers

6.3.1 Unmet Need

6.3.2 Gap Analysis

6.3.3 Opportunity

6.4 Treatment Options for Squamous Patients in the First-Line and Third-Line Setting

6.4.1 Unmet Need

6.4.2 Gap Analysis

6.4.3 Opportunity

6.5 Alternative Testing Options for Patients with Insufficient Biopsy Material

6.5.1 Unmet Need

6.5.2 Gap Analysis

6.5.3 Opportunity

6.6 Treatments for Patients with Acquired Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance

6.6.1 Unmet Need

6.6.2 Gap Analysis

6.6.3 Opportunity

7 Pipeline Assessment

7.1 Overview

7.2 Promising Drugs in Clinical Development

7.2.1 Immune Checkpoint Inhibitors

7.2.2 Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

7.2.3 Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors

7.2.4 Therapeutic Cancer Vaccines

7.2.5 Anti-angiogenic Therapies

7.2.6 Avastin (bevacizumab) Biosimilars

7.2.7 KRAS Inhibitors

7.2.8 Tafinlar (dabrafenib) + Mekinist (trametinib)

7.2.9 Veliparib (ABT-888)

7.2.10 Seribantumab (MM-121)

7.2.11 IMMU-132 (sacituzumab govitecan)

7.2.12 Plinabulin (NPI-2358)

7.3 Promising Drugs in Early-Stage Development

7.3.1 Immune Checkpoint Inhibitors

7.3.2 Anaplastic Lymphoma Kinase Inhibitors

7.3.3 Neurotropic Tropomyosin-Related Kinase Inhibitors

7.3.4 MET inhibitors

7.3.5 Rearranged During Transfection Inhibitors

7.3.6 Human Epidermal Growth Factor 2 Inhibitors

7.3.7 PI3K Pathway Inhibitors

8 Market Outlook

8.1 US

8.1.1 Forecast

8.1.2 Key Events

8.1.3 Drivers and Barriers

9 Appendix

9.1 Bibliography

9.2 Abbreviations

9.3 Methodology

9.4 Forecasting Methodology

9.4.1 Diagnosed NSCLC Patients

9.4.2 Percent Drug-Treated Patients

9.4.3 Drugs Included in Each Therapeutic Class

9.4.4 Launch and Patent Expiry Dates

9.4.5 General Pricing Assumptions

9.4.6 Individual Drug Assumptions

9.4.7 Generic Erosion

9.4.8 Pricing of Pipeline Agents

9.5 Primary Research - KOLs

9.5.1 KOLs

9.6 About the Authors

9.6.1 Analyst

9.6.2 Therapy Area Director

9.6.3 Epidemiologist

9.6.4 Global Head of Healthcare

9.7 About the Author

9.8 Disclaimer

1.1 List of Tables

Table 1: Definitions Used in the AJCC Lung Cancer Staging System

Table 2: AJCC Staging of NSCLC

Table 3: Symptoms of NSCLC

Table 4: Prognostic Factors for NSCLC

Table 5: Prognosis for NSCLC Based on Initial Staging

Table 6: Prevalence of Brain and Bone Metastases in NSCLC

Table 7: Biomarker Testing Rates in Nonsquamous NSCLC

Table 8: Biomarker Testing Rates in Squamous NSCLC

Table 9: Treatment Guidelines for NSCLC

Table 10: Most Prescribed Drugs for NSCLC by Class in the 8MM, 2015-2025

Table 11: Country Profile - US

Table 12: Leading Treatments for NSCLC, 2016

Table 13: Marketed EGFR TKIs in NSCLC

Table 14: Product Profile - Tarceva

Table 15: Efficacy of Tarceva in First-Line Therapy, EGFR-mutant NSCLC

Table 16: Efficacy of Tarceva in Maintenance Therapy in NSCLC

Table 17: Efficacy of Tarceva in Second- and Third-Line Therapy in NSCLC

Table 18: Safety of Tarceva

Table 19: Tarceva SWOT Analysis, 2016

Table 20: Product Profile - Iressa

Table 21: Efficacy of Iressa in First-Line, EGFR-Mutant NSCLC (Study 1)

Table 22: Efficacy of Iressa in First-Line, EGFR-Mutant ADC NSCLC (Study 2)

Table 23: Safety of Iressa

Table 24: Iressa SWOT Analysis, 2016

Table 25: Product Profile - Gilotrif

Table 26: Efficacy of Gilotrif in First-Line, EGFR-Mutant ADC

Table 27: Efficacy of Gilotrif in First-Line, EGFR-Mutant ADC

Table 28: Efficacy of Gilotrif in Second-Line, EGFR-Wildtype, EGFR TKI-Naïve, Squamous NSCLC

Table 29: Efficacy of Gilotrif in Fourth-Line, EGFR-Mutant NSCLC

Table 30: Safety of Gilotrif

Table 31: Gilotrif SWOT Analysis, 2016

Table 32: Product Profile - Tagrisso

Table 33: Efficacy of Tagrisso in Second-Line, EGFR-Mutant NSCLC

Table 34: Safety of Tagrisso

Table 35: Tagrisso SWOT Analysis, 2016

Table 36: Product Profile - Portrazza

Table 37: Efficacy of Portrazza in First-Line, Squamous NSCLC

Table 38: Safety of Portrazza

Table 39: Portrazza SWOT Analysis, 2016

Table 40: Efficacy of Conmana in 2L Advanced NSCLC

Table 41: Efficacy of Conmana in 1L EGFR-mutant NSCLC

Table 42: Safety of Conmana

Table 43: Conmana SWOT Analysis, 2016

Table 44: Marketed ALK TKIs in NSCLC

Table 45: Product Profile - Xalkori

Table 46: Efficacy of Xalkori in Treatment-Naïve ALK+ Metastatic NSCLC

Table 47: Efficacy of Xalkori in Previously Treated ALK+ Metastatic NSCLC

Table 48: Safety of Xalkori in Treatment-Naïve, ALK+ Metastatic NSCLC

Table 49: Safety of Xalkori in Previously Treated, Metastatic NSCLC

Table 50: Xalkori SWOT Analysis, 2016

Table 51: Product Profile - Zykadia

Table 52: Efficacy of Zykadia

Table 53: Safety of Zykadia

Table 54: Zykadia SWOT Analysis, 2016

Table 55: Product Profile - Alecensa

Table 56: Efficacy of Alecensa

Table 57: Efficacy of Alecensa in NSCLC patients with CNS lesions

Table 58: Safety of Alecensa

Table 59: Alecensa SWOT Analysis, 2016

Table 60: Marketed PD-1/PD-L1 ICIs in NSCLC

Table 61: Product Profile - Opdivo

Table 62: Efficacy of Opdivo in Metastatic Squamous NSCLC

Table 63: Efficacy of Opdivo in Metastatic Nonsquamous NSCLC

Table 64: Safety of Opdivo

Table 65: Opdivo SWOT Analysis, 2016

Table 66: Product Profile - Keytruda

Table 67: Efficacy of Keytruda

Table 68: Safety of Keytruda

Table 69: Keytruda SWOT Analysis, 2016

Table 70: Product Profile - Tecentriq (atezolizumab)

Table 71: Patient Demographics in the Phase II POPLAR Trial (NCT01903993)

Table 72: Efficacy of Tecentriq in the Phase II POPLAR Trial (NCT01903993)

Table 73: Efficacy of Tecentriq in the Phase III OAK Trial (NCT02008227)

Table 74: Patient Demographics in the Phase II FIR Trial (NCT01846416)

Table 75: Efficacy of Tecentriq in the Phase II FIR Trial (NCT01846416)

Table 76: Efficacy of Tecentriq in the Phase II BIRCH Trial (NCT02031458)

Table 77: Safety of Tecentriq in the Phase II POPLAR Trial (NCT01903993)

Table 78: Safety of Tecentriq in the Phase II FIR Trial (NCT01846416)

Table 79: Tecentriq SWOT Analysis, 2016

Table 80: Product Profile - Avastin

Table 81: Efficacy of Avastin in Nonsquamous NSCLC

Table 82: Safety of Avastin

Table 83: Avastin SWOT Analysis, 2016

Table 84: Product Profile - Cyramza

Table 85: Efficacy of Cyramza

Table 86: Safety of Cyramza

Table 87: Cyramza SWOT Analysis, 2016

Table 88: Product Profile - Vargatef

Table 89: Efficacy of Vargatef in ADC NSCLC

Table 90: Safety of Vargatef in ADC NSCLC

Table 91: Vargatef SWOT Analysis, 2016

Table 92: Summary of Chemotherapies, 2015

Table 93: Unmet Need and Opportunity in NSCLC

Table 94: Product Profile - Yervoy (ipilimumab)

Table 95: Demographics in the Phase II NCT00527735 Trial

Table 96: Efficacy of Yervoy + Carboplatin + Paclitaxel in Advanced NSCLC (NCT00527735)

Table 97: Demographics in the Phase I CheckMate 012 Trial (NCT01454102)

Table 98: Efficacy of the Opdivo + Yervoy Combination in the CheckMate 012 Trial (NCT01454102)

Table 99: Safety of Yervoy (ipilimumab) + Carboplatin + Paclitaxel in Advanced NSCLC (NCT00527735)

Table 100: Safety of the Opdivo + Yervoy Combination in the CheckMate 012 Trial (NCT01454102)

Table 101: Yervoy SWOT Analysis, 2016

Table 102: Product Profile - Avelumab (MSB-0010718C)

Table 103: Patient Demographics in the Phase Ib Dose-Expansion Study (NCT01772004)

Table 104: Efficacy of Avelumab in the Phase Ib Dose-Expansion Study (NCT01772004)

Table 105: Efficacy of Avelumab in PD-L1-Positive and -Negative NSCLC

Table 106: Demographics in the Treatment-Naïve NSCLC Cohort in the Phase I Trial (NCT01772004)

Table 107: Efficacy of Avelumab in Treatment-Naïve NSCLC

Table 108: Unconfirmed ORR According to PD-L1 Expression in Treatment-Naïve NSCLC

Table 109: Safety of Avelumab in the Phase Ib Dose-Expansion Study (NCT01772004)

Table 110: Safety of Avelumab in Treatment-Naïve NSCLC (NCT01772004)

Table 111: Avelumab SWOT Analysis, 2016

Table 112: Product Profile - Durvalumab (MEDI4736)

Table 113: Patient Demographics and Disease Characteristics in the Phase I/II NCT01693562 Trial

Table 114: Efficacy of Durvalumab in the Phase I/II NCT01693562 Trial

Table 115: Baseline Characteristics of Patients With Treatment-Naïve NSCLC in the Phase I/II

Table 116: Efficacy of Durvalumab in Treatment-Naïve NSCLC

Table 117: Patient Demographics and Disease Characteristics in the Phase Ib NCT02000947 Trial

Table 118: Efficacy of Durvalumab + Tremelimumab in the Phase Ib NCT02000947 Trial

Table 119: Safety of Durvalumab in the Phase I/II Trial (NCT01693562)

Table 120: Safety of Durvalumab in Treatment-Naïve NSCLC

Table 121: Safety of Durvalumab + Tremelimumab in the Phase Ib NCT02000947 Trial

Table 122: Durvalumab SWOT Analysis, 2016

Table 123: Product Profile - Naquotinib Mesylate (ASP8273)

Table 124: Patient Demographics in the Phase I/II NCT02192697 and Phase I NCT02113813 Trials

Table 125: Efficacy of Naquotinib in EGFR-Mutant NSCLC in Japanese and US Patients

Table 126: Safety of Naquotinib in EGFR-Mutant NSCLC in Japanese and US Patients

Table 127: Naquotinib SWOT Analysis, 2016

Table 128: Product Profile - Olmutinib (BI 1482694; HM61713)

Table 129: Demographics in the Phase I/II NCT01588145 Trial

Table 130: Efficacy of Olmutinib in the Phase II Portion of the NCT01588145 Trial

Table 131: Safety Profile of Olmutinib in the Phase II Portion of the NCT01588145 Trial

Table 132: Olmutinib SWOT Analysis, 2016

Table 133: Product Profile - Dacomitinib

Table 134: Demographics in the Phase II NCT00818441 Trial

Table 135: Efficacy of Dacomitinib in the Phase II NCT00818441 Trial

Table 136: Safety of Dacomitinib in Phase II NCT00818441 Trial

Table 137: Dacomitinib SWOT Analysis, 2016

Table 138: Product Profile - Ensartinib

Table 139: Baseline Patient Characteristics in the Phase I/II eXalt2 Trial (NCT0162534)

Table 140: Efficacy of Ensartinib in the Phase I/II eXalt2 Trial (NCT0162534)

Table 141: Baseline Patient Characteristics in the Expansion Cohort of the Phase I/II eXalt2 Trial

Table 142: Efficacy of Ensartinib in the Expansion Phase of the eXalt2 Trial (NCT0162534)

Table 143: Safety of Ensartinib in the Phase I/II eXalt2 Trial (NCT0162534)

Table 144: Ensartinib SWOT Analysis, 2016

Table 145: Product Profile - Brigatinib

Table 146: Baseline Patient Characteristics in the Phase II ALTA Trial (NCT02094573)

Table 147: Efficacy of Brigatinib in the Phase II ALTA Trial (NCT02094573)

Table 148: Efficacy of Brigatinib in ALK+ NSCLC with Intracranial CNS Metastases

Table 149: Safety of Brigatinib in the Phase II ALTA Trial (NCT02094573)

Table 150: Brigatinib SWOT Analysis, 2016

Table 151: Product Profile - CimaVax-EGF

Table 152: Demographics in the Phase III trial of the CimaVax-EGF in Cuba

Table 153: Efficacy of the CimaVax-EGF in the Phase III trial in Cuba

Table 154: Safety of the CimaVax-EGF in the Phase III Trial in Cuba

Table 155: CimaVax-EGF SWOT Analysis, 2016

Table 156: Product Profile - Tedopi

Table 157: Demographics in the Phase II Trial of Tedopi in Advanced NSCLC

Table 158: Efficacy of Tedopi in Advanced NSCLC

Table 159: Tedopi SWOT Analysis, 2016

Table 160: Product Profile - Anlotinib

Table 161: Efficacy of Anlotinib in Pretreated NSCLC in the Phase II ALTER0302 Trial

Table 162: Anlotinib SWOT Analysis, 2016

Table 163: Product Profile - Aitan

Table 164: Efficacy of Aitan in Pretreated Nonsquamous NSCLC

Table 165: Aitan SWOT Analysis, 2016

Table 166: Product Profile - Fruquintinib

Table 167: Baseline Demographics in the Phase I Trial (HMP, NCT01645215) of Fruquintinib

Table 168: Efficacy of Fruquintinib in Advanced Solid Tumors

Table 169: Safety of Fruquintinib in Advanced Solid Tumors

Table 170: Fruquintinib SWOT Analysis, 2016

Table 171: Efficacy and Safety of ABP 215 in NSCLC in the Phase III Trial (NCT01966003)

Table 172: Product Profile - Abemaciclib

Table 173: Efficacy of Abemaciclib Monotherapy in Previously Treated NSCLC (NCT01394016)

Table 174: Efficacy of Abemaciclib in Combination with Other Therapies (NCT02079636)

Table 175: Safety of Abemaciclib in Combination with Multiple Single Agents

Table 176: Abemaciclib SWOT Analysis, 2016

Table 177: Product Profile - Tafinlar + Mekinist

Table 178: Demographics in Cohort B of the Pivotal Phase II BRF113928 Trial (GSK, NCT01336634)

Table 179: Efficacy of Tafinlar + Mekinist in Previously Treated BRAF V600E+ NSCLC

Table 180: Safety of Tafinlar + Mekinist in Previously Treated BRAF V600E+ NSCLC

Table 181: Tafinlar + Mekinist SWOT Analysis, 2016

Table 182: Product Profile - Veliparib

Table 183: Demographics in the Phase II NCT01560104 Trial

Table 184: Efficacy of VCP in Advanced NSCLC (NCT01560104)

Table 185: Efficacy of VCP by Smoking Status (NCT01560104)

Table 186: Safety of VCP in Advanced NSCLC (NCT01560104)

Table 187: Veliparib SWOT Analysis, 2016

Table 188: Product Profile - Seribantumab (MM-121)

Table 189: Demographics in Group A of the Phase I/II Trial (NCT00994123) of MM-121 + Tarceva in

Table 190: Efficacy of MM-121 + Tarceva in EGFR Wild-Type NSCLC

Table 191: Safety of MM-121 + Tarceva in EGFR Wild-Type NSCLC

Table 192: MM-121 SWOT Analysis, 2016

Table 193: Product Profile - Sacituzumab govitecan (IMMU-132)

Table 194: Demographics in the Phase II Portion of the Phase I/II Trial (NCT01631552)

Table 195: Efficacy of IMMU-132 in Pretreated NSCLC in the Phase I/II Trial (NCT01631552)

Table 196: Efficacy of IMMU-132 in Patients Who Progressed on Prior Checkpoint Inhibitor

Table 197: Safety of IMMU-132 in Pretreated NSCLC in the Phase I/II Trial (NCT01631552)

Table 198: IMMU-132 SWOT Analysis, 2016

Table 199: Product Profile - Plinabulin

Table 200: Efficacy of Plinabulin + Docetaxel in the Phase I/II Trial (NCT00630110)

Table 201: Safety of Plinabulin + Docetaxel in the Phase I/II Trial (NCT00630110)

Table 202: Plinabulin SWOT Analysis, 2016

Table 203: Early-Stage Clinical Development in NSCLC

Table 204: MET Status in the Phase II (NCT01610336) Trial

Table 205: Efficacy of Capmatinib + Iressa in MET+ NSCLC

Table 206: Demographics in the Phase II LURET Study

Table 207: Efficacy of Caprelsa in RET+ NSCLC

Table 208: Demographics in the Stage I of the Phase II NCT01639508 Trial

Table 209: Efficacy of Cometriq in RET+ NSCLC

Table 210: Key Events Impacting Sales for NSCLC in the US, 2016

Table 211: NSCLC -Drivers and Barriers in the US, 2015?2025

Table 212: Key Launch Dates - Part I

Table 213: Key Launch Dates - Part II

Table 214: Key Patent Expiries

Table 215 Average Body Weight and Surface Area Across the 8MM

Table 216: Average Cost of Therapy of Alimta in the 8MM

Table 217: Average Cost of Therapy of Alecensa in the 8MM

Table 218: Average Cost of Therapy of Avastin

Table 219: Average Cost of Therapy of Cyramza

Table 220: Average Cost of Therapy of Gilotrif

Table 221: Average Cost of Therapy of Iressa

Table 222: Average Cost of Therapy of Portrazza

Table 223: Average Cost of Therapy of Tagrisso

Table 224: Average Cost of Therapy of Tarceva

Table 225: Average Cost of Therapy of Vargatef

Table 226: Average Cost of Therapy of Xalkori

Table 227: Average Cost of Therapy of Zykadia

Table 228: Average Cost of Therapy of Keytruda

Table 229: Average Cost of Therapy of Opdivo

Table 230: Average Cost of Therapy of Tecentriq

Table 231: Average Cost of Therapy of Conmana

Table 232: High-Prescribing Physicians Surveyed by Country

1.2 List of Figures

Figure 1: Disease Management Flowchart for nonsquamous NSCLC

Figure 2: Disease Management Flowchart for squamous NSCLC

Figure 3: Disease Management Flowchart for EGFR+ NSCLC

Figure 4: Disease Management Flowchart for ALK+ NSCLC

Figure 5: Tarceva’s Phase III Development in NSCLC

Figure 6: Iressa’s Phase II Development in NSCLC

Figure 7: Gilotrif’s Phase III Development in NSCLC

Figure 8: Tagrisso’s Phase III Development in NSCLC

Figure 9: Portrazza’s Phase II Development in NSCLC

Figure 10: Conmana’s Phase III Development in NSCLC

Figure 11: Xalkori’s Development in NSCLC

Figure 12: Zykadia’s Development in NSCLC

Figure 13: Alecensa’s Development in NSCLC

Figure 14: Opdivo’s Development in NSCLC

Figure 15: Keytruda’s Phase III Development in NSCLC

Figure 16: Tecentriq’s Clincal Development in NSCLC

Figure 17: Avastin’s Phase III Development in NSCLC

Figure 18: Cyramza’s Phase III Development in NSCLC

Figure 19: Vargatef’s Phase II Development in NSCLC

Figure 20: NSCLC - Phase II/III Pipeline, 2016, Part I

Figure 21: NSCLC - Phase II/III Pipeline, 2016, Part II

Figure 22: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 2015-2025

Figure 23: Yervoy’s Clinical Development in NSCLC

Figure 24: Clinical and Commercial Positioning of Yervoy

Figure 25: Estimated Sales of Ipilimumab Biosimilars Versus Branded Yervoy in NSCLC, 2015-2025

Figure 26: Avelumab’s Development in NSCLC

Figure 27: Clinical and Commercial Positioning of Avelumab

Figure 28: Durvalumab’s Clinical Development in NSCLC

Figure 29: Clinical and Commercial Positioning of Durvalumab

Figure 30: Naquotinib’s Clincal Development in NSCLC

Figure 31: Clinical and Commercial Positioning of Naquotinib

Figure 32: Olmutinib’s Clincal Development in NSCLC

Figure 33: Clinical and Commercial Positioning of Olmutinib

Figure 34: Dacomitinib’s Clinical Development in NSCLC

Figure 35: Clinical and Commercial Positioning of Dacomitinib

Figure 36: Ensartinib’s Clinical Development in NSCLC

Figure 37: Clinical and Commercial Positioning of Ensartinib

Figure 38: Brigatinib’s Clinical Development in NSCLC

Figure 39: Clinical and Commercial Positioning of Brigatinib

Figure 40: CimaVax-EGF’s Clinical Development in NSCLC

Figure 41: Clinical and Commercial Positioning of CimaVax-EGF

Figure 42: Tedopi’s Clinical Development in NSCLC

Figure 43: Clinical and Commercial Positioning of Tedopi

Figure 44: Anlotinib’s Clinical Development in NSCLC

Figure 45: Clinical and Commercial Positioning of Anlotinib

Figure 46: Aitan’s Clinical Development in NSCLC

Figure 47: Clinical and Commercial Positioning of Aitan

Figure 48: Fruquintinib’s Clinical Development in NSCLC

Figure 49: Clinical and Commercial Positioning of Fruquintinib

Figure 50: Clinical Development of Avastin Biosimilars in NSCLC

Figure 51: Estimated Sales of Bevacizumab Biosimilars Versus Branded Avastin in NSCLC, 2015-2025

Figure 52: Abemaciclib’s Clinical Development in NSCLC

Figure 53: Clinical and Commercial Positioning of Abemaciclib

Figure 54: Tafinlar + Mekinist’s Clinical Development in NSCLC

Figure 55: Clinical and Commercial Positioning of Tafinlar + Mekinist

Figure 56: Veliparib’s Clinical Development in NSCLC

Figure 57: Clinical and Commercial Positioning of Veliparib

Figure 58: MM-121’s Clinical Development in NSCLC

Figure 59: Clinical and Commercial Positioning of MM-121

Figure 60: IMMU-132’s Clinical Development in NSCLC

Figure 61: Clinical and Commercial Positioning of IMMU-132

Figure 62: Plinabulin’s Clinical Development in NSCLC

Figure 63: Clinical and Commercial Positioning of Plinabulin

Figure 64: Sales for NSCLC in the US by Drug Class, 2015-2025
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll